B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

The pace of hepatitis C virus (HCV) drug development in recent years has accelerated
dramatically. For patients to benefit from these impressive advances, practitioners need …

HCV infection, risk-based screening failed to identify the majority of individuals with HCV
infection due to both clinician and patient barriers.(9-12) Analysis of the 2003-2010 National …

Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, for
which whole-genome and—for a subset—whole-transcriptome sequencing data from 2,658 …

Chronic hepatitis C virus (HCV) infection is associated with several extrahepatic
manifestations. Patients with HCV may develop mixed cryoglobulinemia and its sequelae …

Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no
standard treatment exists. MZL is frequently linked to chronic infection, which may induce B …

In February, 2009, 36 scientists from 16 countries met at the International Agency for
Research on Cancer (IARC) to reassess the carcinogenicity of the biological agents …

Chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B lymphocytes,
involves blood, bone marrow, and secondary lymphoid organs such as the lymph nodes …

During hepatitis C virus (HCV) chronic infection, extrahepatic manifestations are frequent
and polymorphous. This article reports on a large cohort of patients with HCV-related …

Direct-acting antiviral (DAA) regimens are safe and effective at eradicating hepatitis C virus
(HCV) infection. Unfortunately, DAAs remain expensive, so treatment of all HCV-infected …